A to Z of CV Pharmacotherapy | Clopidogrel or Ticagrelor: Why, When, for Whom?

  • Видео
  • О видео
  • Скачать
  • Поделиться

A to Z of CV Pharmacotherapy | Clopidogrel or Ticagrelor: Why, When, for Whom?

Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-0000&utm_content=youtube Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor, is the cornerstone of the management of acute coronary syndromes. Despite its proven benefits, the choice of P2Y12 inhibitors remain to be debated over the decades because of the differences in efficacy and safety profiles among these agents. In this 60-minute session by the ISCP focusing on the A to Z of CV Pharmacotherapy, we will examine the differences between clopidogrel and ticagrelor, the two most widely used P2Y12 inhibitors worldwide. We will also identify the patient groups who can benefit most and discuss the optimal treatment duration. This session is the fifth in a series of six webinars from the ISCP focusing on the A to Z of CV Pharmacotherapy. Led by moderators Craig Beavers (USA) and Franco Cheng (Hong Kong), it includes a speaker presentation from Diana A Gorog (UK) and a discussion from panellist Sotiris Antoniou (UK) that will examine the difference between two widely used P2Y12 inhibitors, clopidogrel and ticagrelor, through consideration of real-world examples, live discussions and audience Q&A. This live webinar is EBAC accredited. 1 CME credit will be granted upon confirmation of successful attendance. This is an independent activity run by the International Society of Cardiovascular Pharmacotherapy (ISCP) and co-produced in collaboration with Radcliffe Cardiology. The ISCP has been provided support to deliver this webinar by AstraZeneca UK through an unrestricted educational grant to cover organizational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding. This content is intended for healthcare professionals only. Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
1, 086   |   2 год. назад  |   19 - 0
 

A to Z of CV Pharmacotherapy | Clopidogrel or Ticagrelor: Why, When, for Whom?

Скачайте изображение (превью) выбрав качество


320x180 480x360 640x480 1280x720

Visit Radcliffe Cardiology:

Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor, is the cornerstone of the management of acute coronary syndromes. Despite its proven benefits, the choice of P2Y12 inhibitors remain to be debated over the decades because of the differences in efficacy and safety profiles among these agents. In this 60-minute session by the ISCP focusing on the A to Z of CV Pharmacotherapy, we will examine the differences between clopidogrel and ticagrelor, the two most widely used P2Y12 inhibitors worldwide. We will also identify the patient groups who can benefit most and discuss the optimal treatment duration.

This session is the fifth in a series of six webinars from the ISCP focusing on the A to Z of CV Pharmacotherapy. Led by moderators Craig Beavers (USA) and Franco Cheng (Hong Kong), it includes a speaker presentation from Diana A Gorog (UK) and a discussion from panellist Sotiris Antoniou (UK) that will examine the difference between two widely used P2Y12 inhibitors, clopidogrel and ticagrelor, through consideration of real-world examples, live discussions and audience Q&A.

This live webinar is EBAC accredited. 1 CME credit will be granted upon confirmation of successful attendance.

This is an independent activity run by the International Society of Cardiovascular Pharmacotherapy (ISCP) and co-produced in collaboration with Radcliffe Cardiology. The ISCP has been provided support to deliver this webinar by AstraZeneca UK through an unrestricted educational grant to cover organizational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.


A to Z of CV Pharmacotherapy | Clopidogrel or Ticagrelor: Why, When, for Whom?

Чтобы скачать видео "A to Z of CV Pharmacotherapy | Clopidogrel or Ticagrelor: Why, When, for Whom?" передвинте ползунок вправо



Покажите вашим друзьям, добавьте в соцсети

Ссылка на страницу с видео:

 

Ссылка HTML на страницу с видео:

 

Код для вставки плеера:


  • Комментарии

Комментарии ФБ


Уважаемые друзья!

Источником всего видеоконтента, в том числе проигрывающегося на страницах ресурса ruslar.me, является сторонний видео ресурс, а именно общедоступный видеохостинг YouTube.com, предоставляющий открытый доступ к своему видеоконтенту (используя открытую и общедоступную технологию video API3 youtube.com)!

Проблемы с авторскими правами

Если вам принадлежат авторские права на данное видео, которое было загружено без вашего согласия на YouTube.com, перейдите на страницу этого видео сайта YouTube.com , нажмите на ссылку под проигрывателем Ещё -> "Пожаловаться" -> "Нарушение моих прав" и в выпадающем меню, выбирите, что именно нарушается и нажмите кнопку "Отправить".



Неприемлемый контент

Чтобы сообщить о неприемлемом видео, перейдите на YouTube, нажмите на ссылку под проигрывателем Ещё -> "Пожаловаться" и выберите в "Сообщить о нарушении" что именно вас не устраивает в этом видео. Подробнее о наших правилах читайте в Условиях использования.